These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Comparative bioavailability of two sustained-release theophylline formulations in the dog. Mengozzi G; Intorre L; Bertini S; Giorgi M; Soldani G Pharmacol Res; 1998 Dec; 38(6):481-5. PubMed ID: 9990658 [TBL] [Abstract][Full Text] [Related]
9. Acute and subacute toxicities of theophylline are directly reflected by its plasma concentration in dogs. Shibata M; Wachi M; Kagawa M; Kojima J; Onodera K Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):173-8. PubMed ID: 10893701 [TBL] [Abstract][Full Text] [Related]
10. Comparison of a new sustained-release theophylline preparation, TheoBeads, with Theo-Dur tablets in children with asthma. Welch MJ; Orgel HA; Meltzer EO; Kemp JP; Gawchik S; Rooklin AR; Tinkelman DG J Asthma; 1988; 25(5):269-74. PubMed ID: 3182591 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs. Bach JE; Kukanich B; Papich MG; McKiernan BC J Am Vet Med Assoc; 2004 Apr; 224(7):1113-9. PubMed ID: 15074856 [TBL] [Abstract][Full Text] [Related]
12. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men. Dockhorn RJ; Cefali EA; Straughn AB Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214 [TBL] [Abstract][Full Text] [Related]
13. Sustained-release theophylline for treatment of asthma in preschool children. Simons FE; Luciuk GH; Simons KJ Am J Dis Child; 1982 Sep; 136(9):790-3. PubMed ID: 7114002 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse. Goetz TE; Munsiff IJ; McKiernan BC J Vet Pharmacol Ther; 1989 Dec; 12(4):369-77. PubMed ID: 2614856 [TBL] [Abstract][Full Text] [Related]
15. Invivo absorption behaviour of theophylline from starch-methyl methacrylate matrix tablets in beagle dogs. Fernández-Campos F; Ferrero C; Colom H; Jiménez-Castellanos MR Int J Pharm; 2015 Jan; 478(2):684-92. PubMed ID: 25476254 [TBL] [Abstract][Full Text] [Related]
16. Reversal of acute theophylline toxicity by calcium channel blockers in dogs and rats. Whitehurst VE; Joseph X; Vick JA; Alleva FR; Zhang J; Balazs T Toxicology; 1996 Jun; 110(1-3):113-21. PubMed ID: 8658552 [TBL] [Abstract][Full Text] [Related]
17. Absorption of theophylline from conventional and sustained-release tablets. Mellstrand T; Svedmyr N; Fagerström PO Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088 [TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677 [TBL] [Abstract][Full Text] [Related]
19. High-pressure liquid chromatographic assay of theophylline in dog feces following oral administration of sustained-release products. Chow AT; Meek PD; Jusko WJ J Pharm Sci; 1993 Sep; 82(9):956-8. PubMed ID: 8229696 [TBL] [Abstract][Full Text] [Related]
20. Theophylline QID, TID, BID and now QD? A report on 24-hour dosing with slow-release theophylline formulations with emphasis on analyses of data used to obtain Food and Drug Administration approval for Theo-24. Weinberger MM Pharmacotherapy; 1984; 4(4):181-98. PubMed ID: 6483637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]